Analyst Price Targets — RDNT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 3, 2026 3:56 pm | Brian Tanquilut | Jefferies | $91.00 | $72.01 | StreetInsider | Jefferies Reiterates Buy Rating on RadNet (RDNT); "We remain bullish on RDNT" |
| January 9, 2026 10:35 am | — | UBS | $92.00 | $78.38 | TheFly | RadNet initiated with an Overweight at KeyBanc |
| January 8, 2026 9:14 pm | — | KeyBanc | $92.00 | $78.38 | TheFly | RadNet initiated with an Overweight at KeyBanc |
| December 17, 2025 10:06 am | David MacDonald | Truist Financial | $90.00 | $71.23 | StreetInsider | Truist Securities Reiterates Buy Rating on RadNet (RDNT) |
| November 14, 2025 9:24 am | John Ransom | Raymond James | $95.00 | $73.46 | StreetInsider | RadNet (RDNT) PT Raised to $95 at Raymond James |
| September 3, 2025 1:12 pm | — | Truist Financial | $81.00 | $70.95 | TheFly | RadNet price target raised to $81 from $74 at Truist |
| July 10, 2025 2:00 pm | David MacDonald | Truist Financial | $74.00 | $57.28 | StreetInsider | Truist on RadNet (RDNT): 'Positive EBCD Reimbursement Update From SC' |
| January 22, 2025 1:40 pm | David MacDonald | Truist Financial | $88.00 | $61.77 | TheFly | RadNet price target lowered to $88 from $94 at Truist |
| December 5, 2024 5:10 pm | Brian Tanquilut | Jefferies | $100.00 | $79.16 | StreetInsider | RadNet (RDNT) PT Raised to $100 at Jefferies |
| November 29, 2024 12:13 pm | David MacDonald | Truist Financial | $94.00 | $83.51 | StreetInsider | RadNet (RDNT) PT Raised to $94 at Truist Securities |
Latest News for RDNT
RadNet, Inc. (RDNT) GLEAMER SAS - M&A Call Transcript
LOS ANGELES, March 04, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, reminds investors that on Thursday, March 5, 2026, investors are invited to join a dedicated conference call and presentation to hear more details about the recently completed…
/PRNewswire/ -- USANewsGroup.com News Commentary - AI is making its way through the halls of our entire medical system, and the implementation is accelerating
Eli Lilly and Company's shares rose during the quarter as Zepbound's obesity launch continued to gain strong traction. Cidara Therapeutics' shares rose further following Merck's acquisition of the company in a $9.2 billion all-cash deal announced in November 2025, representing a premium of more than 100% over the prior closing price. Doximity's stock detracted from performance as the company issued disappointing…
RadNet, Inc. (RDNT) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for RDNT.
U.S. House Trading
No House trades found for RDNT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.